Clinical Trial Update: Phase 2 Study of Dacomitinib in NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dacomitinib for non-small cell lung cancer (including EGFR-positive NSCLC) is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dacomitinib (dacomitinib)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: NSCLC Stage IIIB, NSCLC Stage IIIC | Phase 2 | Status: ACTIVE_NOT_RECRUITING